- Home
- LSBK vs TCRX Comparison
LSBK vs TCRX Comparison
Compare LSBK & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSBK
- TCRX
- Stock Information
- Founded
- LSBK 1891
- TCRX 2018
- Country
- LSBK United States
- TCRX United States
- Employees
- LSBK N/A
- TCRX N/A
- Industry
- LSBK Savings Institutions
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- LSBK Finance
- TCRX Health Care
- Exchange
- LSBK Nasdaq
- TCRX Nasdaq
- Market Cap
- LSBK 90.0M
- TCRX 91.7M
- IPO Year
- LSBK 2006
- TCRX 2021
- Fundamental
- Price
- LSBK $13.07
- TCRX $1.89
- Analyst Decision
- LSBK
- TCRX Strong Buy
- Analyst Count
- LSBK 0
- TCRX 5
- Target Price
- LSBK N/A
- TCRX $9.40
- AVG Volume (30 Days)
- LSBK 32.9K
- TCRX 208.8K
- Earning Date
- LSBK 10-22-2025
- TCRX 08-12-2025
- Dividend Yield
- LSBK 2.73%
- TCRX N/A
- EPS Growth
- LSBK 39.59
- TCRX N/A
- EPS
- LSBK 1.05
- TCRX N/A
- Revenue
- LSBK $26,488,000.00
- TCRX $6,961,000.00
- Revenue This Year
- LSBK N/A
- TCRX $255.18
- Revenue Next Year
- LSBK N/A
- TCRX N/A
- P/E Ratio
- LSBK $12.60
- TCRX N/A
- Revenue Growth
- LSBK 1.75
- TCRX N/A
- 52 Week Low
- LSBK $11.50
- TCRX $1.02
- 52 Week High
- LSBK $13.48
- TCRX $6.23
- Technical
- Relative Strength Index (RSI)
- LSBK 58.24
- TCRX 53.95
- Support Level
- LSBK $13.06
- TCRX $1.73
- Resistance Level
- LSBK $13.48
- TCRX $1.96
- Average True Range (ATR)
- LSBK 0.17
- TCRX 0.12
- MACD
- LSBK -0.02
- TCRX 0.01
- Stochastic Oscillator
- LSBK 50.00
- TCRX 66.64
About LSBK Lake Shore Bancorp Inc.
Lake Shore Bancorp Inc operates as a savings and loan holdings company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit and to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.